

UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE, 2002

Rs in million

		Quarter Ended		Year Ended
		30.06.2002	30.06.2001	31.03.2002 (Audited)
1	Net Sales & Income from Operations	4029.5	2991.8	14005.1
2	Other Income	47.8	48.3	283.6
3	Total Expenditure			
	a) (Increase) / decrease in Stock-in -trade	(212.8)	(147.5)	(850.9)
	b) Consumption of Materials	1978.8	1537.7	6907.5
	c) Staff Cost	196.8	154.2	632.5
	d) Other Expenditure	1244.0	861.7	4272.1
4	Interest	2.3	2.5	21.0
5	Depreciation	70.0	47.5	212.8
6	Profit (+) / Loss (-) before Tax (1+2-3-4-5)	798.2	584.0	3093.7
7	Provision for Taxation	191.9	140.0	1017.4
8	Net Profit (+) / Loss (-) (6-7)	606.3	444.0	2076.3
9	Paid-up Equity Share Capital	599.7	599.7	599.7
10	Reserves excluding Revaluation Reserves (as per balance-sheet of previous accounting year)			8616.8
11	Earning per Share * Not Annualised	*10.11	*7.40	34.62

Notes:

- 1 Provision for tax includes deferred taxation
- 2 The Company is exclusively in the pharmaceutical business segment
- 3 The Directors at their meeting held today recommended payment of dividend of Rs.7 per equity share of Rs.10/- each for the year 2001 - 2002 amounting to Rs.419.81 million.
- 4 The figures of the previous year have been regrouped to render them comparable with the figures of the current year.
- 5 The above results were taken on record at the meeting of the Board of Directors held on 24th July, 2002.

By order of the Board
For **CIPLA LIMITED**

Mumbai
24th July, 2002.

M. K. Hamied
Joint Managing Director